{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:28:31Z","timestamp":1792452511178,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor-related overlap syndromes are serious and potentially life-threatening complications of immunotherapy. The available evidence is scarce to guide treatment for refractory cases, and patients often experience poorer outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>We describe two patients who presented with non-specific symptoms of fatigue and weakness. Both exhibited biomarker evidence of skeletal muscle and myocardial injury, along with clinical features suggestive of myasthenia gravis. The patients rapidly deteriorated, requiring admission to the intensive care unit and eventual intubation due to worsening respiratory status. Despite treatment with high-dose intravenous steroids, there was no significant clinical improvement, although early reductions in biomarker levels were observed. This led to the administration of additional therapies, including intravenous immunoglobulin and plasmapheresis, but these interventions were also ultimately ineffective. All testing for myasthenia gravis returned negative, highlighting how patients with primary myositis or overlap myositis with myocarditis can present with bulbar symptoms that closely mimic those of myasthenia gravis. Following multidisciplinary discussions, rituximab was initiated in both cases, which led to successful weaning from mechanical ventilation and eventual discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our case series highlights how patients with primary myositis or overlap myositis with myocarditis may present with bulbar symptoms that can mimic those of myasthenia gravis. Their clinical course was refractory to initial treatments but improved significantly with rituximab. While current guidelines typically recommend biologic therapies targeting T-cell-mediated immunity, our review of literature found a biological basis for targeting antibody-mediated immunity as well. This approach proved effective, enabling both patients to achieve successful discharge after a prolonged and complex hospitalization, highlighting the importance of considering treatment directed at both T-cell and B-cell immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaf593","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T12:59:04Z","timestamp":1763211544000},"source":"Crossref","is-referenced-by-count":3,"title":["Use of rituximab for fulminant and refractory cases of immune checkpoint inhibitor induced myocyte injury clinically presenting with features of myasthenia gravis: a case series"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8873-0090","authenticated-orcid":false,"given":"Imran Naeem","family":"Aziz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, John H Stroger Hospital of Cook County , 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]},{"name":"Division of Translational Science, Rush University Medical College , Armour Academic Center, 600 S. Paulina St., Suite 403, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Gajjar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, John H Stroger Hospital of Cook County , 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]},{"name":"Department of Cardiology , John H Stroger Hospital of Cook County, 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Nandyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, John H Stroger Hospital of Cook County , 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omotola","family":"Oredipe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, John H Stroger Hospital of Cook County , 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seba","family":"Qaddorah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, John H Stroger Hospital of Cook County , 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gedion Yilma","family":"Amdetsion","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, John H Stroger Hospital of Cook County , 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Gomez","family":"Valencia","sequence":"additional","affiliation":[{"name":"Department of Cardiology , John H Stroger Hospital of Cook County, 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tottleben","sequence":"additional","affiliation":[{"name":"Department of Cardiology , John H Stroger Hospital of Cook County, 1969 W Ogden Avenue, Chicago, IL 60612 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2025120812471133300_ytaf593-B1","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025120812471133300_ytaf593-B2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2025120812471133300_ytaf593-B3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025120812471133300_ytaf593-B4","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025120812471133300_ytaf593-B5","doi-asserted-by":"crossref","first-page":"e0272022","DOI":"10.1371\/journal.pone.0272022","article-title":"Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy","volume":"17","author":"Cone","year":"2022","journal-title":"PLoS One"},{"key":"2025120812471133300_ytaf593-B6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025120812471133300_ytaf593-B7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"2025120812471133300_ytaf593-B8","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025120812471133300_ytaf593-B9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025120812471133300_ytaf593-B10","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"2025120812471133300_ytaf593-B11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nmd.2019.10.006","article-title":"Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","author":"Valenti-Azcarate","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2025120812471133300_ytaf593-B12","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.3390\/jcm11195611","article-title":"Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia gravis-like misleading presentation: a case series in intensive care unit","volume":"11","author":"Deharo","year":"2022","journal-title":"J Clin Med"},{"key":"2025120812471133300_ytaf593-B13","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025120812471133300_ytaf593-B14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2025120812471133300_ytaf593-B15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"2025120812471133300_ytaf593-B16","doi-asserted-by":"crossref","first-page":"e002588","DOI":"10.1136\/jitc-2021-002588","article-title":"T follicular helper cells: linking cancer immunotherapy and immune-related adverse events","volume":"9","author":"Baumjohann","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025120812471133300_ytaf593-B17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/imr.13238","article-title":"Role of B cells in immune-related adverse events following checkpoint blockade","volume":"318","author":"Dhodapkar","year":"2023","journal-title":"Immunol Rev"},{"key":"2025120812471133300_ytaf593-B18","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s00262-023-03505-4","article-title":"Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions","volume":"72","author":"Uehara","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2025120812471133300_ytaf593-B19","doi-asserted-by":"crossref","first-page":"107211","DOI":"10.1016\/j.carpath.2020.107211","article-title":"Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: pathway toward precision-based therapy","volume":"47","author":"Balanescu","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"2025120812471133300_ytaf593-B20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/CAD.0000000000001727","article-title":"Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma","volume":"36","author":"Inan","year":"2025","journal-title":"Anticancer Drugs"},{"key":"2025120812471133300_ytaf593-B21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.14740\/jmc4008","article-title":"Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors","volume":"13","author":"Schwab","year":"2022","journal-title":"J Med Cases"},{"key":"2025120812471133300_ytaf593-B22","doi-asserted-by":"crossref","first-page":"2539493","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia Gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Reports Immunol"},{"key":"2025120812471133300_ytaf593-B23","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"2025120812471133300_ytaf593-B24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytaf593\/65354013\/ytaf593.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/12\/ytaf593\/65354013\/ytaf593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/12\/ytaf593\/65354013\/ytaf593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T17:47:27Z","timestamp":1765216047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaf593\/8324918"}},"subtitle":[],"editor":[{"given":"Andriana","family":"Anagnostopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Sho","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Maria Lucia","family":"Narducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Mohammed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Giulia","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaf593","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,17]]},"article-number":"ytaf593"}}